Related Experiment Video
Updated: Sep 20, 2026

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation
Published on: February 28, 2012
Low-dose warfarin prevents recurrent thromboembolism
1Department of Pharmacy, School of Pharmacy, Virginia Commonwealth University, Richmond, USA. mplum@vcu.edu
Low-intensity warfarin (target international normalized ratio [INR], 1.5-2.0) effectively prevents recurrent venous thromboembolism without increasing the risk of major bleeding when used long-term for secondary prophylaxis. This is a reasonable approach following at least 3 to 12 months of full-intensity warfarin after the initial thromboembolic event.
Low-intensity warfarin (target international normalized ratio [INR], 1.5-2.0) effectively prevents recurrent venous thromboembolism without increasing the risk of major bleeding when used long-term for secondary prophylaxis. This is a reasonable approach following at least 3 to 12 months of full-intensity warfarin after the initial thromboembolic event.
Related Concept Videos
Anticoagulant Drugs: Low-Molecular-Weight Heparins
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Venous Thrombosis III: Interprofessional Care
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Pulmonary Embolism III: Nursing Management
Venous Thrombosis IV: Nursing Management